Combination therapy with KRAS inhibitors for the treatment of cancer

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. It is a large subset of diseases characterized by the uncontrollable growth of abnormal cells. RAS is a well-known proto-oncogene and its gain-of-function mutations occur in approximately 30% of all human cancers. The most frequently mutated RAS isoform is KRAS, which constitutes 86% of RAS mutations. KRAS-4B is the dominant isoform in human cancers, and it is present in approximately 90% of pancreatic cancers, 30% to 40% of colon cancers, and 15% to 20% of lung cancers, mostly non-small-cell lung cancer (NSCLC). It is also present in biliary tract malignancies, endometrial cancer, cervical cancer, bladder cancer, liver cancer, myeloid leukemia and breast cancerThe present invention relates to the field of cancer and, more particularly, to a combination comprising Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) inhibitors and Omomyc and its use in medicine, more particularly in the prevention and/or treatment of cancer